Cargando…

Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS

Detalles Bibliográficos
Autores principales:	Cheung, Chee Kay, Nettleton, Katie J., Williams, Matthew L., Page, Amy S., Littler, Yvonne, Goodlife, Andrea, Singhal, Tanu, Brunskill, Nigel J., Carr, Susan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933456/ https://www.ncbi.nlm.nih.gov/pubmed/31891011 http://dx.doi.org/10.1016/j.ekir.2019.08.020

Ejemplares similares

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
por: Teoh, Chia Wei, et al.
Publicado: (2018)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
por: Benoit, Stefanie W., et al.
Publicado: (2022)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016)

Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab
por: Umscheid, Jacob H., et al.
Publicado: (2021)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis
por: Sadiq, Sanober, et al.
Publicado: (2023)

Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS
por: Favi, Evaldo, et al.
Publicado: (2022)

Can eculizumab be discontinued in aHUS?: Case report and review of the literature
por: Sahutoglu, Tuncay, et al.
Publicado: (2016)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
por: Lokki, A. Inkeri, et al.
Publicado: (2020)

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
por: Kelen, Dorottya, et al.
Publicado: (2021)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011)

Genetics and complement in atypical HUS
por: Kavanagh, David, et al.
Publicado: (2010)

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
por: Bouwmeester, Romy N., et al.
Publicado: (2022)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
por: Fakhouri, Fadi, et al.
Publicado: (2021)

Atypical HUS relapse triggered by COVID-19
por: Ville, Simon, et al.
Publicado: (2021)

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
por: Durán, Carlos E., et al.
Publicado: (2012)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Atypical HUS Associated with CFH/CFHR-1 Hybrid Gene
por: Negi, Sharon, et al.
Publicado: (2020)

Atypical HUS Triggered by COVID-19: A Case Report
por: Tiwari, Vaibhav, et al.
Publicado: (2022)

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
por: Manière, Louis, et al.
Publicado: (2019)

COVID-19 as a potential trigger of complement-mediated atypical HUS
por: El Sissy, Carine, et al.
Publicado: (2021)

Pulmonary Renal Syndrome due to Atypical HUS in a Young Gentleman
por: Rajarajan, Arun P., et al.
Publicado: (2023)

Atypical HUS and Crohn’s disease—interference of intestinal disease activity with complement-blocking treatment
por: Horváth, Orsolya, et al.
Publicado: (2021)

Treatment of atypical uraemic syndrome in the era of eculizumab
por: Fremeaux-Bacchi, Veronique
Publicado: (2012)

Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
por: Yenerel, Mustafa N.
Publicado: (2014)

Eculizumab as rescue therapy in a kidney transplant recipient with atypical hemolytic uremic syndrome: a case report
por: Oh, Young Ju, et al.
Publicado: (2022)

Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
por: Azad, Farhan, et al.
Publicado: (2023)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016)

Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)

Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017)

Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
por: Gomes, Sara Madureira, et al.
Publicado: (2021)

The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022)

Long-term Use of Eculizumab in Kidney Transplant Recipients
por: Milan Manani, Sabrina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jbknnu0nga7hhib7p45j5n8a5e